期刊文献+

TACE治疗巨大肝癌60例疗效及预后因素分析 被引量:7

Predictors of survival after chemoembolization of huge hepatocellular carcinoma-α series of 60 cases
暂未订购
导出
摘要 为了研究肝动脉化疗栓塞(transcatheter arterial chemoembolization,TACE)治疗巨大原发性肝癌的效果及预后因素,对1998年9月~2004年12月TACE治疗的直径≥100mm的60例原发性肝癌患者的临床资料进行回顾分析,log-rank单因素分析影响预后的因素,多因素分析采用cox比例风险模型确定独立的危险因素。结果显示TACE治疗后的1年、2年、3年生存率分别为41.7%、14.7%和7.3%。Child-pugh分级、有无门脉栓子、TACE术后4d白蛋白下降程度是影响预后的独立因素。TACE治疗巨大肝癌的疗效尚不令人满意,应用大剂量碘油不能提高巨大肝癌患者的生存时间,有门静脉栓子和肝脏储备功能差的患者手术后的预后较差。 The objective of this study was to investigate the efficacy of chemoembolization in the treatment of huge HCC and analyze the survival predictors. From September 1998 to December 2004, a series of sixty pathologically confirmed HCC patients with a diameter of 10 cm or larger treated with TACE were retrospectively studied. Log-rank univariable analysis and Cox regression analysis were performed to determine the predictors of survival. The 1-, 2- and 3- year survival rates of the patients with huge HCC after TACE were 41.7%, 14.7% and 7.3%, respectively. High Child-pugh scores, existence of portal vein thrombi and drastic decrease of serum albumin after the first TACE were the factors predicting poor survival independently. In conclusion, TACE is not very effective in subset of patients with huge HCC. Increased lipiodol dosage is not related to longer survive and those patients with poor liver function reservation are of poor survival period as expected.
出处 《中华肿瘤防治杂志》 CAS 2007年第22期1734-1735,共2页 Chinese Journal of Cancer Prevention and Treatment
关键词 肝肿瘤/治疗 栓塞 治疗性 预后 liver neoplasms/therapy embolization, therapeutic prognosis
  • 相关文献

参考文献5

二级参考文献23

  • 1孙玉萍,申红.多肿瘤标志物蛋白芯片检测系统在胃癌诊断和病情监测中的价值[J].肿瘤防治杂志,2004,11(7):703-705. 被引量:13
  • 2左强,李爱民,蔡红兵,郑航,卢惠芳,罗荣城.TPA或TPS联合蛋白芯片检测系统对原发性肝癌的诊断价值[J].肿瘤防治杂志,2005,12(5):355-359. 被引量:1
  • 3刘崎,贾雨辰,贺佳,王振堂,田建明,叶华,陆建平,王飞,杨继金,孙飞,陈栋,林琳.肝癌合并门脉癌栓的化疗栓塞治疗[J].中华放射学杂志,1995,29(4):239-242. 被引量:82
  • 4刘崎 贾雨辰 等.肝癌侵犯门静脉的影像表面及其临床意义[J].中华放射学杂志,1991,25:152-155.
  • 5Katyal S, Oliver JH, Peterson MS, et al. Prognostic significance of arterial phase CT for prediction of response to transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma. AJR,2000,175 : 1665-1672.
  • 6Vogl TJ, Trapp M, Schroeder H, et al. Transarterial chemoembolization for hepatocellular carcinoma: volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success - results from a liver transplantation center. Radiology, 2000, 214:349-357.
  • 7Chung JW, Park JH, Im JG, et al. Pulmonary oil embolism after transcatheter oily chemoembolization of hepatocellular carcinoma.Radiology, 1993, 187: 689-693.
  • 8Nakao N, Uchida H, Kamino K, et al. Determination of the optimum dose of Lipiodol in transcatheter arterial embolization of primary hepatocellular carcinoma based on retrospective multivariate analysis. Cardiovasc Intervent Radiol, 1994, 17:76-80.
  • 9Matsuo N, Uchida H, Sakaguchi H, et al. Optimal lipiodol volume in transcatheter arterial chemoembolotherapy for hepatocellular carcinoma: study based on lipiodol accumulation patterns and histopathologic findings. Semin Oncol, 1997, 24: 61-70.
  • 10Chung J W,AJR,1995年,165卷,315321页

共引文献84

同被引文献64

引证文献7

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部